Stock disconnect triggers investor exodus from CStone Pharma
The share price fell nearly 40% in a week after the drugs company was dropped from a scheme allowing mainland investors to trade Hong Kong-listed stocks Key Takeaways: CEO Jason…
Recent Articles
RELATED ARTICLES
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
-
Hong Kong’s Café de Coral takes go-slow approach to Mainland dining market
0341.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
